Trending...
- Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series - 139
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion - 111
- Image Printing Company, Inc. Awarded GSA Multiple Award Schedule Contract, Expanding Federal Printing Capabilities - 111
LIVONIA, Mich.--(BUSINESS WIRE)--Hygieia, a digital therapeutics company for insulin therapy, has successfully licensed its d-Nav insulin management technology to Movement Group, a provider of health and wellness programs to integrated health delivery networks in Israel. The agreement is part of an accelerated strategy to expand its d-Nav insulin titration technology globally.
d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations to correspond to a patient's changing insulin needs. Patients get the correct insulin dose at each injection, without the need for physician intervention. Studies have shown that nearly 90 percent of d-Nav patients have improved A1C levels within 90 days*, without increasing the risk for hypoglycemia**.
Movement currently offers a diabetes prevention program. The d-Nav license agreement enables Movement to add an insulin management program to its existing services. Movement is offering the program to patients within the largest integrated managed care and delivery networks in Israel.
More on Michimich.com
To assist in expanding the d-Nav Technology internationally, Hygieia has appointed technology entrepreneur Gilad Lederer as its new head of global business development. Lederer is the co-founder of OTM Technologies, Ltd., and an investor in and advisor to several technology and private equity companies.
"This agreement with Movement extends access to potentially lifesaving technology for patients in Israel with type 2 diabetes taking insulin," said Lederer. "This is an exciting chapter in Hygieia's international journey, and we are looking for additional partners worldwide to license the d-Nav Technology."
On the heels of the Movement agreement is the news that the National Health Service in Northern Ireland extended its d-Nav license. Northern Ireland's NHS was the first international licensee of the d-Nav Technology.
Many patients from Northern Ireland who have been on the d-Nav program for more than seven years continue to show excellent results with an average A1C at 7% throughout their time on the program.
Organizations and providers that license d-Nav Technology receive complete information and ongoing consultation on how to build the insulin management program around the d-Nav Technology. For more information, contact +1-734-743-2838.
About Hygieia/ d-Nav Insulin Management Program
Hygieia is the developer of d-Nav®, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav's AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body's changing insulin needs. Studies have shown that nearly 90 percent of people using d-Nav report lower A1C in just three months* without increasing the risk for hypoglycemia**. The d-Nav Insulin Management Program has been peer-reviewed with studies published in leading medical journals. Hygieia is headquartered in Livonia, Michigan. Learn more at d-Nav.com.
More on Michimich.com
* John E Schneider et al. Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses. J Health Econ Outcomes Res. 2018 Feb 20;6(1):53-62. https://jheor.org/article/9783
** Richard M Bergenstal et al. Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. Lancet 2019 Mar 16;393(10176):1138-1148. https://pubmed.ncbi.nlm.nih.gov/30808512/
Contacts
Debbie Reinheimer, debbie@reinheimerpr.com
d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations to correspond to a patient's changing insulin needs. Patients get the correct insulin dose at each injection, without the need for physician intervention. Studies have shown that nearly 90 percent of d-Nav patients have improved A1C levels within 90 days*, without increasing the risk for hypoglycemia**.
Movement currently offers a diabetes prevention program. The d-Nav license agreement enables Movement to add an insulin management program to its existing services. Movement is offering the program to patients within the largest integrated managed care and delivery networks in Israel.
More on Michimich.com
- LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
- GDE Tree Services Expands Operations into Sydney, NSW
- Tuckwell Machinery Expands CNC Range to Support Australian Cabinet Makers
- Pure Michigan Lawn Care Offers Limited-Time Discounts for New Customers in Howell, MI
- Pure Michigan Lawn Care Launches Lawn Care and Seasonal Cleanup Services in Howell, MI
To assist in expanding the d-Nav Technology internationally, Hygieia has appointed technology entrepreneur Gilad Lederer as its new head of global business development. Lederer is the co-founder of OTM Technologies, Ltd., and an investor in and advisor to several technology and private equity companies.
"This agreement with Movement extends access to potentially lifesaving technology for patients in Israel with type 2 diabetes taking insulin," said Lederer. "This is an exciting chapter in Hygieia's international journey, and we are looking for additional partners worldwide to license the d-Nav Technology."
On the heels of the Movement agreement is the news that the National Health Service in Northern Ireland extended its d-Nav license. Northern Ireland's NHS was the first international licensee of the d-Nav Technology.
Many patients from Northern Ireland who have been on the d-Nav program for more than seven years continue to show excellent results with an average A1C at 7% throughout their time on the program.
Organizations and providers that license d-Nav Technology receive complete information and ongoing consultation on how to build the insulin management program around the d-Nav Technology. For more information, contact +1-734-743-2838.
About Hygieia/ d-Nav Insulin Management Program
Hygieia is the developer of d-Nav®, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav's AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body's changing insulin needs. Studies have shown that nearly 90 percent of people using d-Nav report lower A1C in just three months* without increasing the risk for hypoglycemia**. The d-Nav Insulin Management Program has been peer-reviewed with studies published in leading medical journals. Hygieia is headquartered in Livonia, Michigan. Learn more at d-Nav.com.
More on Michimich.com
- The Inner Power of Emotional Self-Leadership
- Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
- Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
- Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
* John E Schneider et al. Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses. J Health Econ Outcomes Res. 2018 Feb 20;6(1):53-62. https://jheor.org/article/9783
** Richard M Bergenstal et al. Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. Lancet 2019 Mar 16;393(10176):1138-1148. https://pubmed.ncbi.nlm.nih.gov/30808512/
Contacts
Debbie Reinheimer, debbie@reinheimerpr.com
Filed Under: Business
0 Comments
Latest on Michimich.com
- Shoutout Joseph Neibich aka Nybyk
- Meet Joseph Neibich aka Joseph Nybyk of Beachwood Canyon
- LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
- KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
- Image Printing Company, Inc. Awarded GSA Multiple Award Schedule Contract, Expanding Federal Printing Capabilities
- Logicalis US Named to CRN's Tech Elite 250 for 2026
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
- Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
- New Global Standard for Transparency Across Critical Resources and Energy Markets: SMX (Security Matters) PLC (N A S D A Q: SMX)
- Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
- Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
- Kiko Nation Launches Mobile App to Modernize Livestock Management and Digital Animal Registry
- NEW MANAGEMENT BOOK: Creating a Joy-Centric Culture
- QuickTrack by Datalex Transforms Retail Promoter Management with Claude AI and Real-Time Insights
- Kaltra Introduces Seasonal Discounts on Replacement Coils for Carrier, York, and Trane Chillers
- Evolve Construction Mobilizes Commercial Storm Response Across Illinois With AI-Powered Damage Documentation and Public Adjusters Partnership
- Michigan Faces Challenges From Climate Change: Flooding, Foundation Leaks, And Aging Sewers
- The World's First Fully Regenerative Economy: Securing Energy, Food, and a Clean Planet
- The State of Law Firm Marketing: Top Companies, Awards, and Resources